Emergent BioSolutions Inc. (EBS) stock
Close on Nov 11, 2026Market cap $309.69MP/E –Yield –
Emergent BioSolutions Inc. saw revenue fall 17.7% to $649.10M over the twelve months to Sep 30, 2026. Operating income fell 251.7% to -$179.80M, moving the operating margin from 15.0% to -27.7%. Free cash flow was $188.40M, up 13357.1% from a year earlier. At the latest close the market valued the company at $309.69M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $309.69M
- P/E ratio
- –
- Price to sales
- 0.48
- Price to book
- 0.99
- Dividend yield
- –
- Free cash flow yield
- 60.83%
Fundamentals
- Revenue
- $649.10M
- Net income
- -$260.70M
- EPS, diluted
- -$5.02
- Free cash flow
- $188.40M
- Book value per share
- $6.11
- Diluted shares
- 51M
Trading
- Next earnings
- Feb 25, 2027 (estimated, after the close)
- Previous close
- $6.05
- Open
- $6.06
- Day's range
- $6.00 – $6.12
- Volume
- 516,260
- Average volume (20 days)
- 1,130,484
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 1.84
- 52-week range
- $4.36 – $14.06
- RSI (14 days)
- 42.5
- Volatility (1 year)
- 69.1%
- Relative volume
- 0.45×
- WACC
- 9.7%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EBS | S&P 500 | Difference | EBS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.4% | -2.4% | −12.0 pts | ||
| 3 months | +35.7% | -1.2% | +36.9 pts | ||
| Year to date | -51.1% | +12.3% | −63.4 pts | ||
| 1 year | -44.5% | +12.4% | −56.9 pts | ||
| 3 years | +202.0% | +78.8% | +123.2 pts | +44.5% | +21.4% |
| 5 years | -83.0% | +75.2% | −158.1 pts | -29.8% | +11.9% |
| 10 years | -80.5% | +311.1% | −391.6 pts | -15.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Emergent BioSolutions filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Update
- News
- Results
About Emergent BioSolutions
Pharmaceutical Preparations
The company is a life sciences enterprise that develops and supplies medical solutions to address public health threats, including chemical, biological, and nuclear hazards, infectious diseases, and emergency health crises. Its operations comprise three primary segments: Commercial Products, Medical Countermeasures, and Services. The Commercial segment supplies opioid overdose treatments, notably NARCAN and KLOXXADO nasal sprays. The Medical Countermeasures segment provides vaccines and therapeutics against severe threats such as smallpox, anthrax, and botulism, featuring ACAM2000, BioThrax, and BAT. The Services segment delivers contract development and manufacturing capabilities for external clients. Its customers include the United States government, foreign governments, healthcare departments, law enforcement agencies, community organizations, pharmacies, and commercial biopharmaceutical companies.
Company profile, executives and historyEmergent BioSolutions stock: common questions
What is Emergent BioSolutions's stock price?
EBS closed at $6.04 on Nov 11, 2026, down 0.17% on the day. Over the past 52 weeks it traded between $4.36 and $14.06.
What is Emergent BioSolutions's market cap?
Emergent BioSolutions was worth $309.69M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is EBS's P/E ratio?
Emergent BioSolutions lost money over the twelve months to Sep 30, 2026 (diluted EPS -$5.02), so it has no meaningful P/E ratio.
How much revenue does Emergent BioSolutions make?
Emergent BioSolutions reported revenue of $649.10M for the twelve months to Sep 30, 2026, down 17.7% from a year earlier.
Does Emergent BioSolutions pay a dividend?
No. Emergent BioSolutions has not paid a cash dividend over the last twelve months.
When does Emergent BioSolutions report earnings next?
Emergent BioSolutions is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has EBS stock performed over the past year?
Including dividends, EBS returned -44.5% over the past year, against +12.4% for the S&P 500.
How many EBS shares are sold short?
10M shares were sold short at the latest FINRA report, 20.91% of the float, or 10.1 days of average trading volume.
Who are Emergent BioSolutions's competitors?
Companies most similar to Emergent BioSolutions by business, industry and size include AMPH, OPK, AAPG, PBH, ORGO.
See a number that looks wrong?